These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34933813)

  • 1. Surgical Safety of Deferred Cytoreductive Nephrectomy Following Pretreatment with Immune Checkpoint Inhibitor-based Dual Combination Therapy.
    Graafland NM; Szabados B; Tanabalan C; Kuusk T; Mumtaz F; Barod R; Nicol D; Boleti E; Powles T; Haanen JB; Bex A
    Eur Urol Oncol; 2022 Jun; 5(3):373-374. PubMed ID: 34933813
    [No Abstract]   [Full Text] [Related]  

  • 2. Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
    Yanagisawa T; Schmidinger M; Kawada T; Bekku K; Kimura T; Shariat SF
    Eur Urol Focus; 2023 Mar; 9(2):275-277. PubMed ID: 36775716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Swinging Pendulum: Bringing Back Cytoreductive Nephrectomy in the Era of Immune Checkpoint Inhibition.
    Pallauf M; Ged Y; Singla N
    Eur Urol Oncol; 2022 Oct; 5(5):585-586. PubMed ID: 35965196
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6.
    Ghoreifi A; Djaladat H
    Eur Urol; 2023 Aug; 84(2):e53-e54. PubMed ID: 37149463
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Liu J; Moon D; Lawrentschuk N
    Eur Urol; 2023 Aug; 84(2):244-245. PubMed ID: 37088596
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Ziad Bakouny, Talal El Zarif, Shaan Dudani, et al. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2023;83:145-51.
    Li J; Chen B; Cao D
    Eur Urol; 2023 Sep; 84(3):e75. PubMed ID: 37270390
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis.
    Fallah J; Gittleman H; Weinstock C; Chang E; Agrawal S; Tang S; Pazdur R; Kluetz PG; Suzman DL; Amiri-Kordestani L
    J Natl Cancer Inst; 2024 Jul; 116(7):1043-1050. PubMed ID: 38486364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial.
    Iisager L; Ahrenfeldt J; Donskov F; Ljungberg B; Bex A; Lund L; Lyskjær I; Fristrup N
    BMC Cancer; 2024 Feb; 24(1):260. PubMed ID: 38402173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study.
    Hatakeyama S; Naito S; Numakura K; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Tsushima E; Nishiyama H; Ito A; Kojima Y; Habuchi T; Obara W; Tsuchiya N; Ohyama C
    Int J Urol; 2021 Apr; 28(4):369-375. PubMed ID: 33314387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elective Cytoreductive Nephrectomy After Checkpoint Inhibitor Immunotherapy in Patients With Initially Unresectable Metastatic Clear Cell Renal Cell Carcinoma.
    Reimers MA; Figenshau RS; Kim EH; Tucker J; Kasten N; Khan AS; Hanneken JM; Smith ZL; Hsieh JJ
    Clin Genitourin Cancer; 2020 Oct; 18(5):361-366. PubMed ID: 32417157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).
    De Bruijn RE; Mulders P; Jewett MA; Wagstaff J; Van Thienen JV; Blank CU; Van Velthoven R; Wood L; van Melick HE; Aarts MJ; Lattouf JB; Powles T; De Jong IJ; Rottey S; Tombal B; Marreaud S; Collette S; Collette L; Haanen JB; Bex A
    Eur Urol; 2019 Oct; 76(4):437-440. PubMed ID: 31227307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?
    Mollica V; Rizzo A; Massari F
    Eur Urol Oncol; 2020 Aug; 3(4):559-560. PubMed ID: 32553708
    [No Abstract]   [Full Text] [Related]  

  • 13. Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC.
    Das A; Shapiro DD; Craig JK; Abel EJ
    Nat Rev Urol; 2023 Nov; 20(11):654-668. PubMed ID: 37400492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three Years After CARMENA: What Have We Learned?
    Roussel E; Beuselinck B; Albersen M
    Eur Urol; 2021 Oct; 80(4):425-427. PubMed ID: 34325948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis.
    Mori K; Quhal F; Yanagisawa T; Katayama S; Pradere B; Laukhtina E; Rajwa P; Mostafaei H; Sari Motlagh R; Kimura T; Egawa S; Bensalah K; Karakiewicz PI; Schmidinger M; Shariat SF
    Int Immunopharmacol; 2022 Jul; 108():108720. PubMed ID: 35339843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Graham J; Bhindi B; Heng DYC
    Curr Opin Urol; 2019 Sep; 29(5):507-512. PubMed ID: 31305275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?
    Pignot G; Thiery-Vuillemin A; Walz J; Lang H; Bigot P; Werle P; Balssa L; Geoffrois L; Leblanc L; Albigès L; di Nunno V; Bensalah K; Ladoire S; Gravis G; Barthélémy P
    Eur Urol; 2020 Jun; 77(6):761-763. PubMed ID: 31911011
    [No Abstract]   [Full Text] [Related]  

  • 18. Cytoreductive nephrectomy: future directions.
    Margulis V; Hakimi AA
    Curr Opin Urol; 2019 Sep; 29(5):540-541. PubMed ID: 31305272
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CANCER].
    Nosov AK; Novik AV; Vorobiev AV; Samartseva EE; Reva SA; Baldueva IA; Lushina PA
    Vopr Onkol; 2015; 61(3):494-8. PubMed ID: 26242167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.